Standard of Care IV antihypertensive — Competitive Intelligence Brief

Standard of Care IV antihypertensive (Standard of Care IV antihypertensive) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ACE inhibitor. Area: Cardiovascular.

phase 3 ACE inhibitor AT1 receptor Cardiovascular Small molecule

Target snapshot

Standard of Care IV antihypertensive (Standard of Care IV antihypertensive) — The Medicines Company. Blocks the action of angiotensin II at its receptor, leading to vasodilation and decreased blood pressure.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Standard of Care IV antihypertensive TARGET	Standard of Care IV antihypertensive	The Medicines Company	phase 3	ACE inhibitor	AT1 receptor
Edarbi	AZILSARTAN MEDOXOMIL	Arbor Pharms Ireland	marketed	Angiotensin 2 Receptor Blocker	AT1 receptor	2011-01-01
Cozaar	losartan	Merck & Co.	marketed	ARB (Angiotensin II receptor blocker)	AT1 receptor	1995-04-14
olmesartan medoxomil+probenecid	olmesartan medoxomil+probenecid	Central South University	marketed	Angiotensin II receptor blocker + uricosuric agent	AT1 receptor (angiotensin II type 1 receptor); uric acid transporter (URAT1)
Candesartan cilexetil / hydrochlorothiazide	Candesartan cilexetil / hydrochlorothiazide	Takeda	marketed	Angiotensin II receptor antagonist / thiazide diuretic combination	AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter
VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE	VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE	Novartis	marketed	Angiotensin II receptor blocker (ARB) + thiazide diuretic	AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter (NCC)
Candesartan cilexetil/Amlodipine besylate	Candesartan cilexetil/Amlodipine besylate	HK inno.N Corporation	marketed	Angiotensin II receptor blocker / Calcium channel blocker combination	AT1 receptor (angiotensin II type 1 receptor) / L-type voltage-gated calcium channel

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2028-03-26 — Edarbi · 9066936 · US
• 2030-02-04 — Edarbi · 9169238 · US
• 2031-07-01 — Edarbi · 9387249 · US

Sponsor landscape (ACE inhibitor class)

1. Boryung Pharmaceutical Co., Ltd · 5 drugs in this class
2. Bioprojet · 2 drugs in this class
3. Ain Shams University · 2 drugs in this class
4. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 drug in this class
5. Beijing Tide Pharmaceutical Co., Ltd · 1 drug in this class
6. Children's Hospital of Fudan University · 1 drug in this class
7. Ache Laboratorios Farmaceuticos S.A. · 1 drug in this class
8. Daewon Pharmaceutical Co., Ltd. · 1 drug in this class
9. Ethicare GmbH · 1 drug in this class
10. Ace Cells Lab Limited · 1 drug in this class